[go: up one dir, main page]

TN2009000530A1 - N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors - Google Patents

N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors

Info

Publication number
TN2009000530A1
TN2009000530A1 TNP2009000530A TN2009000530A TN2009000530A1 TN 2009000530 A1 TN2009000530 A1 TN 2009000530A1 TN P2009000530 A TNP2009000530 A TN P2009000530A TN 2009000530 A TN2009000530 A TN 2009000530A TN 2009000530 A1 TN2009000530 A1 TN 2009000530A1
Authority
TN
Tunisia
Prior art keywords
compound
treatment
piperidinedicarboxamide
ethoxyethyl
pyridinyl
Prior art date
Application number
TNP2009000530A
Other languages
English (en)
Inventor
Fumiaki Yokokawa
Takeru Ehara
Shimpei Kawakami
Osamu Irie
Masaki Suzuki
Yuko Hitomi
Atsushi Toyao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39926743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000530(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2009000530A1 publication Critical patent/TN2009000530A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TNP2009000530A 2007-06-25 2009-12-17 N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors TN2009000530A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07012412 2007-06-25
EP07111290 2007-06-28
PCT/EP2008/057964 WO2009000811A1 (fr) 2007-06-25 2008-06-23 Composés organiques

Publications (1)

Publication Number Publication Date
TN2009000530A1 true TN2009000530A1 (en) 2011-03-31

Family

ID=39926743

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000530A TN2009000530A1 (en) 2007-06-25 2009-12-17 N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors

Country Status (26)

Country Link
US (2) US8383650B2 (fr)
EP (2) EP2527338B1 (fr)
JP (1) JP5086433B2 (fr)
KR (1) KR101238479B1 (fr)
CN (1) CN101687847B (fr)
AR (1) AR067132A1 (fr)
AU (1) AU2008267287B2 (fr)
BR (1) BRPI0813900A2 (fr)
CA (1) CA2689109A1 (fr)
CL (1) CL2008001872A1 (fr)
CO (1) CO6251267A2 (fr)
CR (1) CR11153A (fr)
CU (1) CU23842B1 (fr)
EA (1) EA016446B1 (fr)
EC (1) ECSP099825A (fr)
ES (2) ES2543641T3 (fr)
GT (1) GT200900324A (fr)
HN (1) HN2009003463A (fr)
IL (1) IL202494A0 (fr)
MA (1) MA31538B1 (fr)
NZ (1) NZ582098A (fr)
PE (1) PE20090425A1 (fr)
SG (1) SG182223A1 (fr)
TN (1) TN2009000530A1 (fr)
TW (1) TWI404714B (fr)
WO (1) WO2009000811A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2543641T3 (es) 2007-06-25 2015-08-20 Novartis Ag Derivados de N5-(2-etoxietil)-N3-(2-piridinil)-3,5-piperidinadicarboxamida para uso como inhibidores de renina
US20180048921A1 (en) * 2016-08-12 2018-02-15 Microsoft Technology Licensing, Llc Real-time playback diagnostics

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE141269T1 (de) 1991-12-18 1996-08-15 Schering Corp Imidazolyl oder imidazolylalkyl substituiert mit einem 4- oder 5-gliedrigen stickstoff enthaltenden heterozyklischen ring
IL111176A0 (en) 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
CA2230931C (fr) 1995-09-07 2009-05-19 F. Hoffmann-La Roche Ag Nouvelles 4-(oxyalcoxyphenyl)-3-oxy-piperidines utiles pour traiter l'insuffisance cardiaque et renale
WO1997018813A1 (fr) 1995-11-22 1997-05-29 Merck & Co., Inc. Inhibiteurs de la farnesyl-proteine transferase
CA2298813A1 (fr) 1997-08-28 1999-03-04 Merck & Co., Inc. Modulateurs de pyrrolidine et de piperidine de l'activite du recepteur de chemokine
CA2333554A1 (fr) 1998-06-17 1999-12-23 Chu-Baio Xue Acides hydroxamiques cycliques utilises en tant qu'inhibiteurs de metalloproteases
US6274735B1 (en) 1998-08-10 2001-08-14 Hoffmann-La Roche Inc. Process and intermediates for preparation of substituted piperidines
EP1124822A4 (fr) 1998-10-30 2002-04-03 Merck & Co Inc Inhibiteurs de la thrombine
WO2000051607A1 (fr) 1999-03-02 2000-09-08 Merck & Co., Inc. Modulateurs de l'activite recepteur des chimiokines, a base de 3-cyclopropyle et 3-cyclobutyle
US6303593B1 (en) 1999-03-02 2001-10-16 Merck & Co., Inc. 3-thienyl and 3-furanyl pyrrolidine modulators of chemokine receptor activity
WO2000051610A1 (fr) 1999-03-02 2000-09-08 Merck & Co., Inc. Modulateurs de l'activite de recepteurs de chemokine a base de pyrrolidine
AU3818900A (en) 1999-04-14 2000-11-02 F. Hoffmann-La Roche Ag Process for the preparation of substituted piperidines
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
NZ521248A (en) 2000-03-17 2004-04-30 Bristol Myers Squibb Pharma Co Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha
FR2811673B1 (fr) 2000-07-17 2002-09-13 Rhodia Chimie Sa Utilisation de composes insatures comprenant un heterocycle comme stabilisants de polymeres halogenes
WO2002034716A2 (fr) 2000-10-11 2002-05-02 Merck & Co., Inc. Modulateurs a base de pyrrolidine d'activite de recepteur de chimiokines ccr5
US20060079533A1 (en) 2001-03-23 2006-04-13 Nieman James A Methods of treating alzheimer's disease
WO2002088101A2 (fr) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de bace
US6740649B2 (en) 2001-09-17 2004-05-25 Bristol-Myers Squibb Company Cyclic hydroxamic acids as inhibitors of matrix metalloproteinases and/or TNF- α converting enzyme (TACE)
WO2003031443A1 (fr) 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Antibiotiques a action duale renfermant une oxazolidinone et une quinolone ou une fraction de naphthyridinone
HRP20041132A2 (en) 2002-04-29 2006-07-31 Actelion Pharmaceuticals Ltd. 7-aryl-3, 9-diazabicyclo (3.3.1) non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
PL213029B1 (pl) 2002-05-20 2012-12-31 Bristol Myers Squibb Co Podstawiona pochodna cykloalkilowa, zawierajaca ja kompozycja oraz ich zastosowanie
AU2003259131A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US20040214832A1 (en) 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
JP2006524656A (ja) 2003-04-28 2006-11-02 アクテリオン　ファマシューティカルズ　リミテッド 新規ジアザビシクロノネンおよびテトラヒドロピリジン誘導体
CN1972912A (zh) 2003-04-29 2007-05-30 埃科特莱茵药品有限公司 新型3,4－二取代的1,2,3,6－四氢吡啶衍生物
US20060205768A1 (en) 2003-04-30 2006-09-14 Olivier Bezencon Tropane derivatives and their use as ace inhibitors
CN1780837A (zh) 2003-04-30 2006-05-31 埃科特莱茵药品有限公司 新型氮杂二环壬烯衍生物
AU2004233575A1 (en) 2003-04-30 2004-11-11 Actelion Pharmaceuticals Ltd 9-azabicyclo'3.3.1!non-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors
JP2006525259A (ja) 2003-05-02 2006-11-09 アクテリオン　ファマシューティカルズ　リミテッド 新規ジアザビシクロノネン誘導体
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
CN1863773A (zh) 2003-10-09 2006-11-15 埃科特莱茵药品有限公司 四氢吡啶衍生物
KR20060120146A (ko) 2003-11-26 2006-11-24 노파르티스 아게 레닌 억제제로서의 4-페닐피페리딘 유도체
EP1689702B1 (fr) 2003-11-26 2013-01-30 Novartis AG Composés organiques
EP1711456A2 (fr) 2004-01-23 2006-10-18 Speedel Experimenta AG Derives d' amino alcohol et leur utilisation comme inhibiteurs de la renine
BRPI0507067A (pt) 2004-01-23 2007-06-12 Speedel Experimenta Ag diamino álcoois e seu uso como inibidores de renina
JP2007520487A (ja) 2004-01-23 2007-07-26 シュペーデル・エクスペリメンタ・アーゲー アミノアルコール誘導体およびレニン阻害剤としてのその活性
BRPI0508961A (pt) 2004-03-19 2007-08-14 Speedel Experimenta Ag derivados de 5-amino-4-hidróxi-7-(1h-indolmetil)-8-metilnonamida como inibidores de renina para o tratamento de hipertensão
BRPI0508969A (pt) 2004-03-19 2007-08-21 Speedel Experimenta Ag compostos orgánicos
TW200613274A (en) 2004-07-09 2006-05-01 Speedel Experimenta Ag Organic compounds
TW200631929A (en) 2004-12-10 2006-09-16 Speedel Experimenta Ag ω -phenyloctanamides
GB0428250D0 (en) 2004-12-23 2005-01-26 Novartis Ag Organic compounds
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0500784D0 (en) 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0504850D0 (en) 2005-03-09 2005-04-13 Novartis Ag Organic compounds
JP2008532983A (ja) 2005-03-11 2008-08-21 シュペーデル・エクスペリメンタ・アーゲー レニン阻害剤として有用な複素環置換アルカンアミド
GB0505969D0 (en) 2005-03-23 2005-04-27 Novartis Ag Organic compounds
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
AR053836A1 (es) 2005-03-31 2007-05-23 Speedel Experimenta Ag Piperdinas 3,4,5-sustituidas
GB0508992D0 (en) * 2005-05-03 2005-06-08 Novartis Ag Organic compounds
GB0510810D0 (en) 2005-05-26 2005-06-29 Novartis Ag Organic compounds
GB0511063D0 (en) 2005-05-31 2005-07-06 Novartis Ag Organic compounds
GB0514203D0 (en) * 2005-07-11 2005-08-17 Novartis Ag Organic compounds
WO2007031558A1 (fr) 2005-09-17 2007-03-22 Speedel Experimenta Ag Amides d'acide alcanoïque bicyclo- ou spiro-substitués
BRPI0616219A2 (pt) 2005-09-17 2011-06-14 Speedel Experimenta Ag amidas de Ácidos alcanàicos substituÍdas por o-heterociclos saturados
PE20071079A1 (es) * 2005-11-15 2007-12-16 Cytokinetics Inc Compuestos de piperidina como inhibidores de la proliferacion celular
PE20071177A1 (es) * 2005-12-30 2008-01-18 Novartis Ag Derivados de 3,5-piridina como inhibidores de renina
EP1816122A3 (fr) 2006-01-19 2007-09-19 Speedel Experimenta AG Pipéridines substituées 3,4,5 en tant que composants thérapeutiques
TW200740767A (en) 2006-01-30 2007-11-01 Speedel Experimenta Ag Process for the preparation of organic compounds
WO2007141318A1 (fr) 2006-06-08 2007-12-13 Speedel Experimenta Ag Pipéridines 2,5-disubstituées
GB0611697D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
GB0611696D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
TW200831463A (en) 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols
EP1908471A1 (fr) 2006-10-04 2008-04-09 Speedel Experimenta AG Tétrahydropyridines comme inhibiteurs de la renine
EP1921069A1 (fr) 2006-11-08 2008-05-14 Speedel Experimenta AG Procédé de préparation de 2-alkyl-3-hétérocyclyl-prop-2-èn-1-ols
WO2008113835A1 (fr) 2007-03-21 2008-09-25 Novartis Ag Procédé de préparation de la (r ou s)-5-{1-azido-3-[6-méthoxy-5-(3-méthoxy-propoxy)-pyridin-3-ylméthyl]-4-méthyl-pentyl}-3-alkyl-dihydro-furan-2-one
ES2543641T3 (es) 2007-06-25 2015-08-20 Novartis Ag Derivados de N5-(2-etoxietil)-N3-(2-piridinil)-3,5-piperidinadicarboxamida para uso como inhibidores de renina

Also Published As

Publication number Publication date
EP2527338A1 (fr) 2012-11-28
US8497286B2 (en) 2013-07-30
GT200900324A (es) 2011-11-03
NZ582098A (en) 2012-03-30
EA016446B1 (ru) 2012-05-30
IL202494A0 (en) 2010-06-30
CO6251267A2 (es) 2011-02-21
ES2543641T3 (es) 2015-08-20
SG182223A1 (en) 2012-07-30
JP5086433B2 (ja) 2012-11-28
ECSP099825A (es) 2010-01-29
KR20100023003A (ko) 2010-03-03
AU2008267287A1 (en) 2008-12-31
WO2009000811A1 (fr) 2008-12-31
BRPI0813900A2 (pt) 2014-12-30
PE20090425A1 (es) 2009-05-12
JP2010531328A (ja) 2010-09-24
CA2689109A1 (fr) 2008-12-31
EP2181105A1 (fr) 2010-05-05
US20130005770A1 (en) 2013-01-03
AR067132A1 (es) 2009-09-30
CU23842B1 (es) 2012-10-15
CR11153A (es) 2010-01-21
HN2009003463A (es) 2012-12-10
CN101687847A (zh) 2010-03-31
US20080319018A1 (en) 2008-12-25
TW200911782A (en) 2009-03-16
MA31538B1 (fr) 2010-07-01
TWI404714B (zh) 2013-08-11
EA201000037A1 (ru) 2010-06-30
KR101238479B1 (ko) 2013-03-04
EP2181105B1 (fr) 2015-04-29
EP2527338B1 (fr) 2015-05-06
AU2008267287B2 (en) 2012-02-16
CN101687847B (zh) 2013-11-06
US8383650B2 (en) 2013-02-26
CL2008001872A1 (es) 2009-02-20
ES2541107T3 (es) 2015-07-16
CU20090226A7 (es) 2012-02-15

Similar Documents

Publication Publication Date Title
GEP20125425B (en) Biaryl ether urea compounds
MX2009006401A (es) Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer.
TNSN06411A1 (en) Pyrimidine urea derivatives as kinase inhibitors
BRPI0813244B8 (pt) compostos derivados de pirazinona, composições compreendendo ditos compostos, uso dos compostos no tratamento de doenças de pulmão e composto intermediário
MX2009010059A (es) Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
TW200833663A (en) Therapeutic agents
MY155649A (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
WO2005075425A3 (fr) Derives de bisaryluree
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
WO2011127333A3 (fr) Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques
EP2349279A4 (fr) Modulateurs d'aldéhyde déshydrogénase et procédés d'utilisation de ceux-ci
MX2008013212A (es) 4-anilinquinolina-3-carboxamidas como inhibidores de la cinsa csf-1r.
TW200738698A (en) Organic compounds
WO2006072589A3 (fr) Urees disubstituees utilisees en tant qu'inhibiteurs de kinase
MX2012003324A (es) Compuesto de glicina.
TNSN07419A1 (en) Methods for treating drug resistant cancer
GB0428250D0 (en) Organic compounds
WO2006085113A3 (fr) Composes chimiques
MX2007011009A (es) Compuestos de piperidina 3,4,5-substituidos.
MA32406B1 (fr) Composés contenant de l'azote tricyclique et utilisation de ceux-ci comme antibactériens
WO2010121675A3 (fr) Thiazolyl-benzimidazoles
MXPA05010020A (es) Derivados de oxamida.
WO2006125621A8 (fr) Piperidines substituees utilisees comme inhibiteurs de la renine
MX2008011020A (es) Compuestos de receptor sigma.